Drug Trial Radar · NCT06149663
Intermediate-Size Expanded Access Protocol (EAP) for LP352
Last checked: Nov 19, 2026Latest source record: Jan 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Available
Enrollment
Not stated
Start
Not stated
Primary completion
Not stated
Sponsor
- Lead sponsor
- Longboard PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Nov 29, 2023
Design
- Study type
- Expanded access
- Who can join
- All sexes, from 2 years, up to 65 years
Summary
As written by the sponsor on the registry.
This is an intermediate-size expanded access program (EAP) study. The purpose of this EAP is to provide continued access to LP352, an investigational drug product being investigated in participants with DEEs. The EAP study will allow continued treatment with LP352 for eligible participants diagnosed with treatment resistant DEEs who successfully completed an LP352 Clinical Trial (Enrollment by Invitation) or an immediate family member who has the exact same gene mutation resulting in the same DEE epilepsy syndrome phenotype or a patient who previously participated in the lorcaserin EAP.
Conditions
- Dravet Syndrome
- Lennox Gastaut Syndrome
- Developmental and Epileptic Encephalopathies
Interventions
LP352Drug
LP352 will be administered as a liquid either orally or through a G-tube or Percutaneous Endoscopic Gastrotomy (PEG) tube.
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
22 sites in 2 countries. Site status is shown where the registry gives one.
Rancho Research Institute
Downey, California · Available
University of California Los Angeles (UCLA)
Los Angeles, California · Available
University of California Benioff Childrens Hospital
San Francisco, California · Available
Colorados Childrens Hospital
Aurora, Colorado · Available
Northwest Florida Clinical Research Group
Gulf Breeze, Florida · Available
Research Institute of Orlando
Orlando, Florida · Available
University of Southern Florida
Tampa, Florida · Available
Hawaii Pacific Neuroscience
Honolulu, Hawaii · Available
Northwestern Medicine Feinberg School of Medicine
Chicago, Illinois · Available
Mid-Atlantic Epilepsy and Sleep Center
Bethesda, Maryland · Available
Corewell Health
Grand Rapids, Michigan · Available
Washington University School of Medicine
St Louis, Missouri · Available
New York University (NYU)
New York, New York · Available
Lenox Hill Hospital
New York, New York · Available
University Hospitals Cleveland Medical Center
Cleveland, Ohio · Available
Providence Brain & Spine
Portland, Oregon · Available
Thomas Jefferson University
Philadelphia, Pennsylvania · Available
Children's Neuro Consultants of Austin
Austin, Texas · Available
University of Utah
Salt Lake City, Utah · Available
Austin Hospital, Heidelberg
Heidelberg, Melbourne, Australia · Available
Alfred Hospital
Melbourne, Melbourne, Australia · Available
Children's Health Queensland Hospital and Health Service,
South Brisbane, Queensland, Australia · Available
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.